Considering the relevance of a dysregulated circadian clock in the development of gliomas and its clinical research, we will review potential anti-GBM agents that target the clock molecular machinery in GBM patients, and that may be applied in the future chronotherapy regimes for GBM. The gene discussed is CLOCK; the disease is central nervous system cancer.